KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:开放图源暂不可得 入排置信度 0.98

A phase III double-blind, placebo-controlled, randomized withdrawal trial of 5‑aminolevulinic acid hydrochloride with sodium ferrous citrate for efficacy and safety in patients diagnosed as Leigh syndrome.

Akira Ohtake, Yuichi Abe, Kei Murayama, Hideaki Shiraishi, Hitoshi Osaka, Satoko Kumada, Tetsuya Ito, Hidehito Kondo, Yusuke Hamada, Sayaka Suzuki-Ajihara, Masato Arao, Yuki Ueda, Kohei Nagai, Keiko Ichimoto, Ayako Matsunaga, Hirofumi Kashii, Yoko Nakajima, Hitoshi Nakagawa, Shunichi Kurose, Kaori Fukuda, Kiwamu Takahashi, Mitsugu Yamauchi, Motowo Nakajima

PLoS One 21(7) e0332283

PMID42467686
PMCIDPMC13379092
DOI10.1371/journal.pone.0332283
发表日期2026-07-17
入排依据:未发现恶性肿瘤人群证据。
PubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。
摘要

摘要

OBJECTIVE: A phase III, double-blind, placebo-controlled, randomized withdrawal trial of SPP‑004 (5‑aminolevulinic acid hydrochloride and sodium ferrous citrate) was conducted to confirm the efficacy and safety of SPP-004 for maintenance of clinical response in patients diagnosed with Leigh syndrome (LS) showing central nervous system disorders. METHODS: Fifty-four patients entered a 24-week open-label period of SPP-004 administration. Among them, 28 patients who showed improvement on the Newcastle Paediatric Mitochondrial Disease Scale (NPMDS) for cranial nervous symptoms and myopathy symptoms proceeded to a 48-week double-blind (DB) period, where they were randomized (1:1) to receive SPP‑004 or placebo (n = 14 each). Efficacy was evaluated using NPMDS for the full analysis set (FAS) during the DB‑period (SPP-004 n = 13, Placebo n = 14) and the entire study period (n = 54). Safety evaluation focused on adverse events (AEs) in all 54 patients administered SPP-004. RESULTS: The primary endpoint, the proportion of patients who discontinued due to inadequate efficacy at 48 weeks, was lower in the SPP-004 group (15.4% [95% CI: 1.9-45.4%]) compared to the placebo group (50.0% [23.0-77.0%]). Over 80% of the SPP-004 group showed maintained efficacy (p = 0.0486). All adverse drug reactions were mild, with no notable differences in AEs between groups. CONCLUSION: These findings suggest that SPP-004 is safe and may provide therapeutic effect for LS patients who achieved an initial clinical response.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。